公开(公告)号：US20240262833A1

公开(公告)日：2024-08-08

申请号：US18559951

申请日：2022-05-13

申请人： Addex Pharma S.A.

发明人： Jean-Laurent Paparin ,  Jean-Philippe Rocher ,  Terry Finn ,  Guillaume Duvey

IPC分类号： C07D487/04 ,  A61K31/5025 ,  A61K31/506

CPC分类号： C07D487/04 ,  A61K31/5025 ,  A61K31/506

摘要： The present invention relates to novel compounds of Formula (I), wherein P, Q, A, B, m, n, R1, R2 and R3 are defined as in Formula (I); which are negative allosteric modulators of the metabotropic glutamate receptor subtype 7 (mGlu7) and which are useful for the treatment or prevention of neurological, ear and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGlu7 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and such compositions, and to the use of such compounds for the prevention or treatment of neurological, ear and psychiatric disorders and diseases in which mGlu7 is involved.

公开(公告)号：US20240327375A1

公开(公告)日：2024-10-03

申请号：US18560011

申请日：2022-05-13

申请人： Addex Pharma S.A.

发明人： Jean-Laurent Paparin ,  Jean-Philippe Rocher ,  Patrick Mäder ,  Tanja Stach ,  Guillaume Duvey ,  Lam Tang

IPC分类号： C07D401/04 ,  A61K31/502 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  C07D237/32 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D403/14 ,  C07D405/04 ,  C07D491/107 ,  C07D498/08

CPC分类号： C07D401/04 ,  A61K31/502 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  C07D237/32 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D403/14 ,  C07D405/04 ,  C07D491/107 ,  C07D498/08

摘要： The present invention relates to novel compounds of Formula (I), wherein A, m, Q, R1, R2, R3, R4 and R5 are defined as in Formula (I); which are negative allosteric modulators of the metabotropic glutamate receptor subtype 7 (mGlu7) and which are useful for the treatment or prevention of neurological, ear and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGlu7 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and such compositions, and to the use of such compounds for the prevention or treatment of neurological, ear and psychiatric disorders and diseases in which mGlu7 is involved.